Recruiting NA INTERVENTIONAL 1-arm
NCT07415837
Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies (Dystro-miR1)
Sponsor: University Hospital, Clermont-Ferrand
Conditions
Congenital Myopathies Duchenne / Becker Muscular Dystrophy Dystrophia Myotonica 1 Healthy Participants
Interventions
dosage of blood biomarker miR1
Updated 1 time since 2026 Last updated: Feb 24, 2026 Started: Feb 11, 2026 Primary completion: Mar 31, 2029 Completion: Mar 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07415837, this NA trial focuses on Congenital Myopathies and Duchenne / Becker Muscular Dystrophy and remains actively recruiting participants. Sponsored by University Hospital, Clermont-Ferrand, it has been updated 1 time since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- University Hospital, Clermont-Ferrand
- iGreD, Université Clermont Auvergne
Data source: University Hospital, Clermont-Ferrand
For direct contact, visit the study record on ClinicalTrials.gov .